Clinical trials: IBD (Inflammatory Bowel Disease)
Inflammatory Bowel Diseases, Ulcerative Colitis
Health-related Physical Fitness in Patients with Inflammatory Bowel Disease
Rationale: Existing literature suggests an impaired health-related physical fitness (HRPF) (i.e., body composition, aerobic capacity, muscular strength, muscular endurance, and flexibility) in patients with inflammatory bowel…
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT05482932
- Testing
- Health-related physical fitness assessment
- Where
- Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Crohn's Disease
Brain-Gut Interactions in Crohn's Disease
The primary aims for this research are to 1) characterize brain changes in patients with CD compared to age and gender-matched controls and 2) relate these brain changes to measures of disease activity and pain severity.
- Trial name
- NCT02108938
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Wisconsin, Madison
Ulcerative Colitis
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease (IBD) characterized by a multifactorial etiology, a variable involvement of large bowel, and a relapsing-remitting course.
- Trial name
- ADVANCED-UC (NCT05931458)
- Testing
- Appendectomy, Infliximab
- Volunteers
- 94 people
- Sponsor
- Federico II University
Crohn Disease
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the…
- Trial name
- CHARGE (NCT07499232)
- Testing
- Guselkumab, Risankizumab
- Where
- 164 sites in United States, Austria and 15 more
- Volunteers
- 530 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).
- Trial name
- InspirAda (NCT01550965)
- Testing
- Adalimumab
- Volunteers
- 463 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Inflammatory Bowel Diseases (IBD), Crohn Disease
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refractory, structurally complicated, postoperative, perianal, pouch-related, or psychosocially complex disease.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Trial name
- DTT-IBD (NCT07877649)
- Testing
- Routine IBD Management and Advanced-Therapy Exposure
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn's Ileocolitis, Crohn Disease
Effect of Statins on Crohn's Disease
The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is: Can statins reduce the formation of strictures in participants with…
- Trial name
- NCT06538649
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Colitis, Ulcerative, Crohn Disease
A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD).
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- INTENT (NCT03532932)
- Where
- 36 sites in Belarus, Kazakhstan and 1 more
- Volunteers
- 1,990 people
- Sponsor
- Takeda
Crohn's Disease
Feasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease
The goal of this clinical trial is to learn whether a camera pill examination of the whole bowel can be used to diagnose Crohn's disease instead of colonoscopy and a small bowel examination (either MRI or camera pill) in patients…
- Trial name
- ANDI-3 (NCT06882993)
- Testing
- Panenteric capsule endoscopy, Ileocolonoscopy, MRI enterography
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 165 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Crohn Disease, Ulcerative Colitis
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe…
- Trial name
- NCT03358706
- Testing
- Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants…
- Trial name
- CHROMA CD (NCT06958536)
- Testing
- brivekimig
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
Ulcerative Colitis
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with…
- Trial name
- NCT00628433
- Testing
- HE3286
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Harbor Therapeutics
Ulcerative Colitis
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC).
- Trial name
- OCTAVE (NCT01458574)
- Testing
- CP690,550, CP-690,550
- Where
- 275 sites in United States, Australia and 29 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis, Diabetes
Health and Exercise Response in Children With Chronic and Auto-immune Pathologies
The aim of the present project is to assess the effects of the chronic diseases and their associated treatments chronic paediatric diseases (CPD), to further understand their impact on physical fitness for public health…
- Conditions
- Juvenile Idiopathic Arthritis, Diabetes, Inflammatory Bowel Disease, Cancer Survivor
- Trial name
- HERCCULE (NCT03913962)
- Testing
- indirect calorimetry
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Healthy
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.
- Trial name
- NCT05536440
- Testing
- PF-07261271
- Where
- 4 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Inflammatory Bowel Diseases
Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease
Objectives: To assess the predictive value of IUS in children with IBD. Design: A prospective longitudinal cohort study. Setting: Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital.
- Trial name
- SPIBDUS (NCT03026582)
- Testing
- Intestinal ultra-sound monitoring
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Schneider Children's Medical Center, Israel
Ulcerative Colitis
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
The aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of filgotinib as a treatment for UC in children and adolescents aged from 8 to less than 18 years.
- Trial name
- Galapeduca (NCT06865417)
- Testing
- Filgotinib
- Where
- 46 sites in Belgium, Croatia and 11 more
- Volunteers
- 80 people
- Sponsor
- Alfasigma S.p.A.
Crohn's Disease
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease
The goal of this observational study is to evaluate the effectiveness and safety of exclusive enteral nutrition (EEN) in adults with active Crohn's disease (CD), particularly in patients with complicated disease such as…
- Trial name
- EEN-CD (NCT07504510)
- Testing
- Exclusive Enteral Nutrition
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
The goal of this observational study is to learn about the mechanism of action of ozanimod in patients with ulcerative colitis (UC). The main questions it aims to answer are: 1.
- Trial name
- NCT06311123
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Crohn Disease
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on…
- Trial name
- NCT02513459
- Testing
- Risankizumab 600 mg IV, Risankizumab 180 mg SC
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.